Currently out of the existing stock ratings of Emily Bodnar, 87 are a BUY (87%), 13 are a HOLD (13%).

Emily Bodnar

Work Performance Price Targets & Ratings Chart

Analyst Emily Bodnar, employed carries an average stock price target met ratio of 22.62% that have a potential upside of 73.59% achieved within 78 days on average. Previously, Emily Bodnar worked at HCWAINWRIGHT.

Emily Bodnar’s has documented 191 price targets and ratings displayed on 16 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VTYX, Ventyx Biosciences at 13-Jun-2024.

Wall Street Analyst Emily Bodnar

Analyst best performing recommendations are on NVCR (NOVOCURE LTD).
The best stock recommendation documented was for VTYX (VENTYX BIOSCIENCES) at 9/1/2022. The price target of $36 was fulfilled within 11 days with a profit of $14.01 (63.71%) receiving and performance score of 57.92.

Average potential price target upside

DICE Dice Molecules Holdings LLC FEMY Femasys NVCR Novocure Ltd OLMA Olema Pharmaceuticals VTYX Ventyx Biosciences SQZ Sqz Biotechnologies Co ACLX Arcellx BCTX Briacell Therapeutics Corp CNTX Context Therapeutics GRCL Gracell Biotechnologies . INKT Mink Therapeutics IOBT IO Biotech NKTX Nkarta  RNAZ Transcode Therapeutics AGEN Agenus SANA Sana Biotechnology

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

48

$0.45 (0.95%)

48

10 months 8 days ago

1/8 (12.5%)

$0.45 (0.95%)

85

Hold

56

11 months 22 days ago

0/1 (0%)

$27.35 (95.46%)

Hold

48

$0.45 (0.95%)

68

11 months 28 days ago

1/3 (33.33%)

$1.56 (3.36%)

27

Hold

48

$0.45 (0.95%)

38

11 months 28 days ago

1/2 (50%)

$1.56 (3.36%)

27

Hold

48

$0.45 (0.95%)

71

11 months 28 days ago

0/2 (0%)

$1.56 (3.36%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Emily Bodnar is most bullish on?

Potential upside of $25.59 has been obtained for ACLX (ARCELLX)

Which stock is Emily Bodnar is most reserved on?

Potential downside of -$0.25 has been obtained for GRCL (GRACELL BIOTECHNOLOGIES .)

What Year was the first public recommendation made by Emily Bodnar?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?